Novartis Tightens Stance Over Gleevec In India

Law360, New York (February 15, 2007, 12:00 AM EST) -- Novartis AG on Thursday strengthened its stance on patenting its cancer treatment Gleevec in India, arguing that a modification to a key section of the country’s patent laws governing whether companies can protect new versions of drugs whose patents have expired would not hinder the supply of essential medicines to poor countries.

Thomas Wellauer, head of corporate services and a member of the executive committee at Novartis, said in a statement Thursday that patents must be respected if research-based organizations are to continue to be able...
To view the full article, register now.